- Home
- MIRM vs EBC Comparison
MIRM vs EBC Comparison
Compare MIRM & EBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRM
- EBC
- Stock Information
- Founded
- MIRM 2018
- EBC 1818
- Country
- MIRM United States
- EBC United States
- Employees
- MIRM N/A
- EBC N/A
- Industry
- MIRM Biotechnology: Pharmaceutical Preparations
- EBC Accident &Health Insurance
- Sector
- MIRM Health Care
- EBC Finance
- Exchange
- MIRM Nasdaq
- EBC Nasdaq
- Market Cap
- MIRM 3.7B
- EBC 3.6B
- IPO Year
- MIRM 2019
- EBC 2020
- Fundamental
- Price
- MIRM $70.45
- EBC $18.20
- Analyst Decision
- MIRM Strong Buy
- EBC Strong Buy
- Analyst Count
- MIRM 11
- EBC 2
- Target Price
- MIRM $82.82
- EBC $21.50
- AVG Volume (30 Days)
- MIRM 596.2K
- EBC 3.2M
- Earning Date
- MIRM 11-04-2025
- EBC 10-23-2025
- Dividend Yield
- MIRM N/A
- EBC 2.98%
- EPS Growth
- MIRM N/A
- EBC N/A
- EPS
- MIRM N/A
- EBC 0.24
- Revenue
- MIRM $471,794,000.00
- EBC $627,584,000.00
- Revenue This Year
- MIRM $53.14
- EBC $27.03
- Revenue Next Year
- MIRM $19.83
- EBC $24.93
- P/E Ratio
- MIRM N/A
- EBC $71.72
- Revenue Growth
- MIRM 53.66
- EBC 3.01
- 52 Week Low
- MIRM $36.88
- EBC $13.51
- 52 Week High
- MIRM $78.55
- EBC $19.40
- Technical
- Relative Strength Index (RSI)
- MIRM 50.06
- EBC 57.94
- Support Level
- MIRM $68.60
- EBC $17.28
- Resistance Level
- MIRM $73.02
- EBC $17.64
- Average True Range (ATR)
- MIRM 3.10
- EBC 0.49
- MACD
- MIRM 0.08
- EBC 0.07
- Stochastic Oscillator
- MIRM 54.27
- EBC 99.36
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
About EBC Eastern Bankshares Inc.
Eastern Bankshares Inc is a commercial bank that caters its products and services to retail, commercial, and small business customers. Its diversified products and services include lending, deposit, wealth management, and insurance products. The company has one operating segment; Banking business which offers a range of banking lending, savings, and small business offerings, and its wealth management and trust operations.